Diaccurate is a spin off from the Pasteur Institute in Paris, France. We work on a new enzymatic mechanism involved in the control of immune responses against HIV and other pathogens. Involvement of this mechanism in the control of tumor growth is also under study. We have discovered in the plasma of immunodeficient patients, a new molecule named RIF (for “Refractory state Inducing Factor”) which by modifying their membrane blocks specifically CD4 lymphocytes responses. Inhibitory monoclonal antibody neutralizing RIF has been characterized and clinical trials should start in 2018.
We plan to recruit highly motivated postdocs for working in the immunological mechanisms behind RIF. Competences in cellular and molecular immunology are required. Previous involvement in preclinical studies would be appreciated.
These positions are located in Paris. Contracts will be from two to four years and gross annual salary between 70 000 € - 80 000 € according to candidate’s experience. Starting date: January 2nd, 2018.
Further details:
Postdoctoral Positions, Diaccurate, France (2018)